Shots:

• Sunovion to receive $270M up front- $620M as development milestone for 4 candidates & is also eligible to receive sales milestone. Sunovion & Otsuka will share profits & expenses for clinical studies- applications for approval- & commercialization in each licensed territories
• Otsuka gets the rights from Sunovion to jointly develop & commercialize 4 compounds globally i.e.- ulotaront (SEP-363856)- SEP-4199- SEP-378614 & SEP-380135 to treat neuropsychiatric disorders
• Sumitomo Dainippon Pharma & Otsuka plan to co-promote 4 candidates jointly where Sumitomo Dainippon will record sales in the US- Canada- Japan & Asia. Otsuka will record sales in 41 other countries and regions including the EU

  | Ref: Otsuka | Image: Wikipedia